Search research articles
Contact Us
Filters
Showing results (231-240 of 362) with videos related to
Page
of 37
Sort By:
Biochemistry
|
April 16, 1998
The bis(naphthalimide) DMP-840 causes cytotoxicity by its action against eukaryotic topoisomerase II
J L Nitiss, J Zhou, A Rose, et al.
Biochemistry
|
March 8, 2000
Action of quinolones against Staphylococcus aureus topoisomerase IV: basis for DNA cleavage enhancement
V E Anderson, R P Zaniewski, F S Kaczmarek, et al.
The Journal of Biological Chemistry
|
September 15, 1995
Abasic sites stimulate double-stranded DNA cleavage mediated by topoisomerase II. DNA lesions as endogenous topoisomerase II poisons
P S Kingma, A H Corbett, P C Burcham, et al.
The Journal of Biological Chemistry
|
December 10, 1999
Quinolones inhibit DNA religation mediated by Staphylococcus aureus topoisomerase IV. Changes in drug mechanism across evolutionary boundaries
V E Anderson, R P Zaniewski, F S Kaczmarek, et al.
The Journal of Biological Chemistry
|
June 14, 2000
Minor groove interactions at the DNA polymerase beta active site modulate single-base deletion error rates
W P Osheroff, W A Beard, S Yin, et al.
Nucleic Acids Research
|
July 31, 2003
Yeast recombination pathways triggered by topoisomerase II-mediated DNA breaks
Michelle Sabourin, John L Nitiss, Karin C Nitiss, et al.
The Journal of Biological Chemistry
|
November 3, 1995
Sensory and motor neuron-derived factor. A novel heregulin variant highly expressed in sensory and motor neurons
W H Ho, M P Armanini, A Nuijens, et al.
Pediatrics
|
August 3, 2006
Lessons from "Unexpected increased mortality after implementation of a commercially sold computerized physician order entry system"
Dean F Sittig, Joan S Ash, Jiajie Zhang, et al.
Biochemistry
|
February 15, 2001
DNA topoisomerase II as the target for the anticancer drug TOP-53: mechanistic basis for drug action
J A Byl, S D Cline, T Utsugi, et al.
Biochemistry
|
November 26, 1999
DNA topoisomerases as targets for the anticancer drug TAS-103: DNA interactions and topoisomerase catalytic inhibition
J M Fortune, L Velea, D E Graves, et al.
Page
of 37
Search research articles
Search
Showing results (231-240 of 362) with videos related to
Sort By:
Page
of 37
Biochemistry
|
April 16, 1998
The bis(naphthalimide) DMP-840 causes cytotoxicity by its action against eukaryotic topoisomerase II
J L Nitiss, J Zhou, A Rose, et al.
Biochemistry
|
March 8, 2000
Action of quinolones against Staphylococcus aureus topoisomerase IV: basis for DNA cleavage enhancement
V E Anderson, R P Zaniewski, F S Kaczmarek, et al.
The Journal of Biological Chemistry
|
September 15, 1995
Abasic sites stimulate double-stranded DNA cleavage mediated by topoisomerase II. DNA lesions as endogenous topoisomerase II poisons
P S Kingma, A H Corbett, P C Burcham, et al.
The Journal of Biological Chemistry
|
December 10, 1999
Quinolones inhibit DNA religation mediated by Staphylococcus aureus topoisomerase IV. Changes in drug mechanism across evolutionary boundaries
V E Anderson, R P Zaniewski, F S Kaczmarek, et al.
The Journal of Biological Chemistry
|
June 14, 2000
Minor groove interactions at the DNA polymerase beta active site modulate single-base deletion error rates
W P Osheroff, W A Beard, S Yin, et al.
Nucleic Acids Research
|
July 31, 2003
Yeast recombination pathways triggered by topoisomerase II-mediated DNA breaks
Michelle Sabourin, John L Nitiss, Karin C Nitiss, et al.
The Journal of Biological Chemistry
|
November 3, 1995
Sensory and motor neuron-derived factor. A novel heregulin variant highly expressed in sensory and motor neurons
W H Ho, M P Armanini, A Nuijens, et al.
Pediatrics
|
August 3, 2006
Lessons from "Unexpected increased mortality after implementation of a commercially sold computerized physician order entry system"
Dean F Sittig, Joan S Ash, Jiajie Zhang, et al.
Biochemistry
|
February 15, 2001
DNA topoisomerase II as the target for the anticancer drug TOP-53: mechanistic basis for drug action
J A Byl, S D Cline, T Utsugi, et al.
Biochemistry
|
November 26, 1999
DNA topoisomerases as targets for the anticancer drug TAS-103: DNA interactions and topoisomerase catalytic inhibition
J M Fortune, L Velea, D E Graves, et al.
Page
of 37